KOHJIN BIO CO LTD (177A.T)
JPY 1703.0
(-0.12%)
JPY 1703.0
(-0.12%)
| Breakdown | 2024 | 2023 | 2022 |
|---|---|---|---|
| Operating Cash Flow | 823.68 Million | 461.15 Million | 762.98 Million |
| Net Income | 635.6 Million | 1.24 Billion | 922.06 Million |
| Depreciation & Amortization | 299.62 Million | 167.58 Million | 179.05 Million |
| Deferred income taxes | - | - | - |
| Stock-based compensation | - | - | - |
| Change in working capital | 473.19 Million | -524.7 Million | -57.23 Million |
| Other non-cash items | -15.23 Million | 45.96 Million | 31.49 Million |
| Investing Cash Flow | -577.35 Million | -575.45 Million | 82.78 Million |
| Investments in PPE | -562.8 Million | -560.71 Million | -203.54 Million |
| Acquisitions | - | - | - |
| Investment purchases | - | -9.99 Million | - |
| Sales/Maturities of investments | - | - | - |
| Other Investing Activities | -14.55 Million | -4.74 Million | 285.04 Million |
| Financing Cash Flow | -1.34 Million | -172.2 Million | -360.17 Million |
| Debt repayment | -110.2 Million | -109.6 Million | -361.6 Million |
| Dividends payments | -79.13 Million | -41.65 Million | -33.85 Million |
| Common Stock Repurchased | - | - | - |
| Common Stock Issuance | - | - | 58.5 Million |
| Other Financing Activities | 267 Million | - | - |
| Accounts receivables | -94 Million | - | - |
| Accounts payables | - | - | - |
| Inventory | 424.89 Million | -581.49 Million | 8.54 Million |
| Other working capital | 9 Million | - | - |
| Cash at beginning of period | 1.46 Billion | 1.73 Billion | 1.21 Billion |
| Cash at end of period | 1.72 Billion | 1.46 Billion | 1.73 Billion |
| Capital Expenditure | -562.8 Million | -560.71 Million | -203.54 Million |
| Effect of forex changes on cash | 19.39 Million | 14.59 Million | 29.2 Million |
| Net cash flow / Change in cash | 264.37 Million | -271.92 Million | 514.79 Million |
| Free Cash Flow | 260.87 Million | -99.56 Million | 559.43 Million |
| Breakdown | 2023 FY | 2023 Q4 | 2022 FY | 2021 FY |
|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - |
| Net Income | 635.6 Million | 177 Million | 1.24 Billion | 922.06 Million |
| Depreciation & Amortization | 299.62 Million | - | 167.58 Million | 179.05 Million |
| Deferred income taxes | - | - | - | - |
| Stock-based compensation | - | - | - | - |
| Change in working capital | 473.19 Million | - | -524.7 Million | -57.23 Million |
| Other non-cash items | -15.23 Million | -177 Million | 45.96 Million | 31.49 Million |
| Investing Cash Flow | -577.35 Million | - | -575.45 Million | 82.78 Million |
| Investments in PPE | -562.8 Million | - | -560.71 Million | -203.54 Million |
| Acquisitions | - | - | - | - |
| Investment purchases | - | - | -9.99 Million | - |
| Sales/Maturities of investments | - | - | - | - |
| Other Investing Activities | -14.55 Million | - | -4.74 Million | 285.04 Million |
| Financing Cash Flow | -1.34 Million | - | -172.2 Million | -360.17 Million |
| Debt repayment | -110.2 Million | - | -109.6 Million | -361.6 Million |
| Dividends payments | -79.13 Million | - | -41.65 Million | -33.85 Million |
| Common Stock Repurchased | - | - | - | - |
| Common Stock Issuance | - | - | - | 58.5 Million |
| Other Financing Activities | 267 Million | - | - | - |
| Accounts receivables | -94 Million | - | - | - |
| Accounts payables | - | - | - | - |
| Inventory | 424.89 Million | - | -581.49 Million | 8.54 Million |
| Other working capital | 9 Million | - | - | - |
| Cash at beginning of period | 1.46 Billion | - | 1.73 Billion | 1.21 Billion |
| Cash at end of period | 1.72 Billion | - | 1.46 Billion | 1.73 Billion |
| Capital Expenditure | -562.8 Million | - | -560.71 Million | -203.54 Million |
| Effect of forex changes on cash | 19.39 Million | - | 14.59 Million | 29.2 Million |
| Net cash flow / Change in cash | 264.37 Million | - | -271.92 Million | 514.79 Million |
| Free Cash Flow | 260.87 Million | - | -99.56 Million | 559.43 Million |
LEI
GED
TRPL3
JAWA
ACT
CHFLF